Skip to content

G&A at other companies

LBR
LB Pharmaceuticals Inc Common StockLBRX
$7.46M+148%
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
$8.93M-4.7%
Alto Neuroscience logo
Alto NeuroscienceANRO
$6.84M+20.0%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$23.82M+25.1%
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
$27.87M+100%
Maze Therapeutics, Inc. Common Stock logo
Maze Therapeutics, Inc. Common StockMAZE
$12.41M+58.6%

Segments

By segment

See full
Employee Related$6.99M+239%
Professional Fees$3.83M+126%

Other financials

Income statement

See full
Operating income-$64.5M-174%
Net income-$60.7M-172%
EPS (diluted)-$1.34+95.4%

Balance sheet

See full
Cash & equivalents$55.7M
Total debt$5.6M
Total equity$399.8M+285%
Total assets$418.8M

Cash flow

See full
Operating cash flow-$51.2M-100%
CapEx$24.0K
Free cash flow-$51.2M

Valuation

See full
Market cap$1.39B+100%
Enterprise value$1.34B

Returns & leverage

See full
Return on equity-216.8%
Debt / equity
Current ratio22.9×

Where this comes from

Reported directly by MapLight Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: MapLight Therapeutics, Inc. ’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about MapLight Therapeutics, Inc. 's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MapLight Therapeutics, Inc. 's G&A?
MapLight Therapeutics, Inc. (MPLT) reported G&A of $10.82M in Q1 2026.
How has MapLight Therapeutics, Inc. 's G&A changed year-over-year?
MapLight Therapeutics, Inc. 's G&A increased by 188.0% year-over-year, from $3.76M to $10.82M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.